Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

被引：4
|
作者：
Foa, Robin [1 ]
Schuh, Anna [2 ]
Zaritskey, Andrey [3 ]
Semochkin, Sergey [4 ]
Simpson, David [5 ]
Egyed, Miklos [6 ]
Vokurka, Samuel [7 ]
Kassis, Jeannine [8 ]
Zhang, Jennie [9 ]
Purse, Brendan [9 ]
Chanan-Khan, Asher A. [10 ]
机构：
[1] Univ Sapienza, Policlin Umberto 1, Rome, Italy
[2] Univ Oxford, Oxford, England
[3] St Petersburg State Med Univ, St Petersburg, Russia
[4] Pirogov Russian Natl Res Med Univ, Moscow, Russia
[5] North Shore Hosp, Auckland, New Zealand
[6] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[7] Univ Hosp Plzen, Plzen, Czech Republic
[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[9] Celgene Corp, Summit, NJ USA
[10] Mayo Clin, Div Hematol, Jacksonville, FL USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
    Lee, Su Jin
    Jung, Chul Won
    Kim, Dae-Young
    Lee, Kyoo-Hyung
    Sohn, Sang Kyun
    Kwak, Jae-Yong
    Kim, Hyeoung-Joon
    Kim, In Ho
    Park, Seonyang
    Kim, Dong Hwan
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (04) : 346 - 350
  • [42] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    Muresan, B.
    Mamolo, C.
    Cappelleri, J. C.
    Postma, M. J.
    Heeg, B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (06) : 929 - 940
  • [43] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    B. Muresan
    C. Mamolo
    J. C. Cappelleri
    M. J. Postma
    B. Heeg
    Applied Health Economics and Health Policy, 2021, 19 : 929 - 940
  • [44] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [45] Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
    Qin, Shukui
    Chen, Zhendong
    Fang, Weijia
    Ren, Zhenggang
    Xu, Ruocai
    Ryoo, Baek-Yeol
    Meng, Zhiqiang
    Bai, Yuxian
    Chen, Xiaoming
    Liu, Xiufeng
    Xiao, Juxiang
    Ho, Gwo Fuang
    Mao, Yimin
    Wang, Xin
    Ying, Jieer
    Li, Jianfeng
    Zhong, Wenyan
    Zhou, Yu
    Siegel, Abby B.
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1434 - +
  • [46] Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.
    Griffin, James D.
    Guerin, Annie
    Chen, Lei
    Macalalad, Alexander R.
    Luo, Jiayuan
    Wu, Eric Qiong
    BLOOD, 2012, 120 (21)
  • [47] Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial
    Blum, Kristie A.
    Wei, Lai
    Jones, Jeffrey A.
    Andritsos, Leslie A.
    Flynn, Joseph M.
    Heerema, Nyla A.
    Yang, Xiaoxia
    Rozewski, Darlene
    Phelps, Mitchell
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    BLOOD, 2011, 118 (21) : 1672 - 1672
  • [48] BENDAMUSTINE VERSUS CHLORAMBUCIL IN TREATMENT- NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED RESULTS OF AN INTERNATIONAL PHASE III STUDY
    Knauf, U.
    Lissichkov, T.
    Aldoud, A.
    Herbrecht, R.
    Liberati, A.
    Loscertales, J.
    Juliusson, G.
    Postner, G.
    Gercheva, L.
    Goranov, S.
    Becker, M.
    Hoeffken, K.
    Huguet, F.
    Foa, R.
    Merkle, K.
    Montillo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 141 - 141
  • [49] Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Benboubker, Lotfi
    Roddie, Huw
    Allietta, Nathalie
    Broer, Esther
    Couturier, Catherine
    Mazier, Marie-Andree
    Angermund, Ralf
    Facon, Thierry
    BLOOD, 2011, 118 (21) : 810 - 811
  • [50] A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease
    Kebriaei, Partow
    Hayes, Jack
    Daly, Andrew
    Uberti, Joseph
    Marks, David, I
    Soiffer, Robert
    Waller, Edmund K.
    Burke, Elizabeth
    Skerrett, Donna
    Shpall, Elizabeth
    Martin, Paul J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (05) : 835 - 844
12345